These data indicate that the group 1 patients with positive clinical and Th1 driven immune responses possibly mobilized and expanded CD4+ TE subsets in response to novel antigens produced as a result of BTZ + TMZ induced tumor cell death. Here, CD4 is linked to neoplasm.